Manish Shah, MD

Manish Shah, MD

Weill Cornell Medicine

Latest Content

Sequencing and next steps for Zanidatamab in HER2-positive gastric cancer with expert oncologists Dr. Manish Shah, Dr. Geoffrey Ku, Dr. Nataliya Uboha, Dr. Rutika Mehta, Dr. Rohit Gosain, and Dr. Rahul Gosain.

ASCO GI 2026: HERIZON-GEA-01

02/01/2026

Ep. 4: Sequencing and Next Steps for Zanidatamab in HER2-Positive Gastric Cancer

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD
HER2-targeted cancer treatment research panel featuring Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Nataliya Uboha, Dr. Rutika Mehta, Dr. Geoffrey Ku, and Dr. Manish Shah discussing HERZON-GEA-01 infusion and GI management for zanidatamab.

ASCO GI 2026: HERIZON-GEA-01

01/30/2026

Ep. 3: HERIZON-GEA-01: Infusion and GI Management for Zanidatamab

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD
1. OncUpdates episode 2 featuring oncology experts discussing managing efficacy and toxicity of Zanidatamab in HER2-positive cancer.

ASCO GI 2026: HERIZON-GEA-01

01/28/2026

Ep. 2: Managing Efficacy and Toxicity With Zanidatamab in HER2-Positive Disease

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD
Zanidatamab first-line therapy for HER2-positive upper GI malignancies discussed by expert panel including Dr. Geoffrey Ku, Dr. Manish Shah, Dr. Natalya Uboha, Dr. Rutika Mehta, Dr. Rohit Gosain, and Dr. Rahul Gosain.

ASCO GI 2026: HERIZON-GEA-01

01/26/2026

Ep. 1: Zanidatamab Redefines First-Line Therapy in HER2-Positive Upper GI Malignancies

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD
Zanidatamab frontline therapy for HER2-positive gastric and GEJ cancer expert panel with Dr. Rutika Mehta, Dr. Nataliya Uboha, Dr. Manish Shah, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Geoffrey Ku.

ASCO GI 2026: HERIZON-GEA-01

01/20/2026

HERIZON-GEA-01: Zanidatamab for HER2+ Advanced Gastroesophageal Cancer

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD